Immune checkpoint inhibitors that target the PD-1/PD-L1 axis overcome inhibition of effector T cell function, in other words, PD-1/PD-L1 inhibitors take the “brakes” off T cells, enabling tumor cell killing. Here, CD274 is linked to neoplasm.